Galliprant

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

grapiprant

Available from:

Elanco GmbH

ATC code:

QM01AX92

INN (International Name):

grapiprant

Therapeutic group:

psi

Therapeutic area:

Druge anti-upalne i противоревматические agenti, bez steroida

Therapeutic indications:

Za liječenje boli povezanih s blago do umjerenim osteoartritisom kod pasa.

Product summary:

Revision: 5

Authorization status:

odobren

Authorization date:

2018-01-09

Patient Information leaflet

                                17 B. UPUTA O VMP
18
UPUTA O VMP:
GALLIPRANT 20
MG TABLETE ZA PSE
GALLIPRANT 60 MG TABLETE ZA PSE
GALLIPRANT 100 MG TABLETE ZA PSE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
Elanco GmbH
Heinz-Lohmann-Str. 4
27472 Cuxhaven
Njemačka
Proizvođač odgovoran za puštanje serije u promet:
Elanco France S.A.S.
26 Rue de la Chapelle
68330 Huningue
Francuska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Galliprant 20 mg tablete za pse
Galliprant 60 mg tablete za pse
Galliprant 100 mg tablete za pse
grapiprant
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Jedna tableta sadržava:
DJELATNA TVAR:
Grapiprant
20 mg
Grapiprant
60 mg
Grapiprant
100 mg
Tableta od 20 mg: bikonveksna ovalna tableta sa smeđim mrljama, na
jednoj strani s razdjelnim
urezom koji razdvaja utisnuti broj „20“ na jednoj polovici i slova
„MG“ na drugoj polovici; na drugoj
strani utisnuto je slovo „G“. Tableta se može podijeliti na
jednake polovice.
Tableta od 60 mg: bikonveksna ovalna tableta sa smeđim mrljama, na
jednoj strani s razdjelnim
urezom koji razdvaja utisnuti broj „60“ na jednoj polovici i slova
„MG“ na drugoj polovici; na drugoj
strani utisnuto je slovo „G“. Tableta se može podijeliti na
jednake polovice.
Tableta od 100 mg: bikonveksna ovalna tableta sa smeđim mrljama, s
utisnutim brojem „100“ na
jednoj polovici i slova „MG“ na drugoj polovici; na drugoj strani
utisnuto je slovo „G“.
19
4.
INDIKACIJA(E)
Za liječenje boli povezane s blagim do umjerenim osteoartritisom
pasa.
5.
KONTRAINDIKACIJE
Ne primjenjivati u slučaju preosjetljivosti na djelatnu tvar ili na
bilo koju od pomoćnih tvari.
Ne primjenjivati na gravidnim i rasplodnim životinjama te onima koje
doje.
6.
NUSPOJAVE
U kliničkim ispitivanjima povraćanje je primijećeno vrlo često,
dok su mekano formirana stolica,
proljev i gubitak volje za hranom primijećen
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Galliprant 20 mg tablete za pse
Galliprant 60 mg tablete za pse
Galliprant 100 mg tablete za pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka tableta sadržava:
DJELATNA TVAR:
Grapiprant
20 mg
Grapiprant
60 mg
Grapiprant
100 mg
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Tableta od 20 mg: bikonveksna ovalna tableta sa smeđim mrljama, na
jednoj strani s razdjelnim
urezom koji odvaja utisnuti broj „20“ na jednoj polovici i slova
„MG“ na drugoj polovici; na drugoj
strani utisnuto je slovo „G“. Tableta se može podijeliti na
jednake polovice.
Tableta od 60 mg: bikonveksna ovalna tableta sa smeđim mrljama, na
jednoj strani s razdjelnim
urezom koji razdvaja utisnuti broj „60“ na jednoj polovici i slova
„MG“ na drugoj polovici; na drugoj
strani utisnuto je slovo „G“. Tableta se može podijeliti na
jednake polovice.
Tableta od 100 mg: bikonveksna ovalna tableta sa smeđim mrljama, s
utisnutim brojem „100“ na
jednoj polovici i slova „MG“ na drugoj polovici; na drugoj strani
utisnuto je slovo „G“.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Pas.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za liječenje boli povezane s blagim do umjerenim osteoartritisom
pasa.
4.3
KONTRAINDIKACIJE
Ne primjenjivati u slučaju preosjetljivosti na djelatnu tvar ili na
bilo koju od pomoćnih tvari.
Ne primjenjivati na gravidnim i rasplodnim životinjama te onima koje
doje . Vidi odjeljak 4.7.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
U većini kliničkih slučajeva, procijenjenih u kliničkim terenskim
ispitivanjima, životinje su bolovale,
prema procjeni veterinara, od blagog do umjerenog osteoartritisa. Da
bi se postigao značajan odgovor
na liječenje, veterinarsko-medicinski proizvod treba primjenjivati
samo u slu
čajevima blagog i
umjerenog osteoartritisa.
U dva klinička terenska ispitivanja sveukupna stopa uspješnosti
temeljena na CBPI-upitniku (
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-08-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-08-2021
Public Assessment Report Public Assessment Report Bulgarian 06-02-2018
Patient Information leaflet Patient Information leaflet Spanish 17-08-2021
Public Assessment Report Public Assessment Report Spanish 06-02-2018
Patient Information leaflet Patient Information leaflet Czech 17-08-2021
Public Assessment Report Public Assessment Report Czech 06-02-2018
Patient Information leaflet Patient Information leaflet Danish 17-08-2021
Public Assessment Report Public Assessment Report Danish 06-02-2018
Patient Information leaflet Patient Information leaflet German 17-08-2021
Public Assessment Report Public Assessment Report German 06-02-2018
Patient Information leaflet Patient Information leaflet Estonian 17-08-2021
Public Assessment Report Public Assessment Report Estonian 06-02-2018
Patient Information leaflet Patient Information leaflet Greek 17-08-2021
Public Assessment Report Public Assessment Report Greek 06-02-2018
Patient Information leaflet Patient Information leaflet English 17-08-2021
Public Assessment Report Public Assessment Report English 06-02-2018
Patient Information leaflet Patient Information leaflet French 17-08-2021
Public Assessment Report Public Assessment Report French 06-02-2018
Patient Information leaflet Patient Information leaflet Italian 17-08-2021
Public Assessment Report Public Assessment Report Italian 06-02-2018
Patient Information leaflet Patient Information leaflet Latvian 17-08-2021
Public Assessment Report Public Assessment Report Latvian 06-02-2018
Patient Information leaflet Patient Information leaflet Lithuanian 17-08-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-08-2021
Public Assessment Report Public Assessment Report Lithuanian 06-02-2018
Patient Information leaflet Patient Information leaflet Hungarian 17-08-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 17-08-2021
Public Assessment Report Public Assessment Report Hungarian 06-02-2018
Patient Information leaflet Patient Information leaflet Maltese 17-08-2021
Public Assessment Report Public Assessment Report Maltese 06-02-2018
Patient Information leaflet Patient Information leaflet Dutch 17-08-2021
Public Assessment Report Public Assessment Report Dutch 06-02-2018
Patient Information leaflet Patient Information leaflet Polish 17-08-2021
Public Assessment Report Public Assessment Report Polish 06-02-2018
Patient Information leaflet Patient Information leaflet Portuguese 17-08-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 17-08-2021
Public Assessment Report Public Assessment Report Portuguese 06-02-2018
Patient Information leaflet Patient Information leaflet Romanian 17-08-2021
Public Assessment Report Public Assessment Report Romanian 06-02-2018
Patient Information leaflet Patient Information leaflet Slovak 17-08-2021
Public Assessment Report Public Assessment Report Slovak 06-02-2018
Patient Information leaflet Patient Information leaflet Slovenian 17-08-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 17-08-2021
Public Assessment Report Public Assessment Report Slovenian 06-02-2018
Patient Information leaflet Patient Information leaflet Finnish 17-08-2021
Public Assessment Report Public Assessment Report Finnish 06-02-2018
Patient Information leaflet Patient Information leaflet Swedish 17-08-2021
Public Assessment Report Public Assessment Report Swedish 06-02-2018
Patient Information leaflet Patient Information leaflet Norwegian 17-08-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 17-08-2021
Patient Information leaflet Patient Information leaflet Icelandic 17-08-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 17-08-2021

Search alerts related to this product

View documents history